Yesafili, a biosimilar to Eylea, received Health Canada's approval, marking the first such approval in Canada. Indicated for ...

Patients express mixed feelings about AI in health care, favoring its use for documentation and administrative tasks while ...

RGN-259 is a thymosin beta-4–based eye drop designed to rival Dompé’s Oxervate, the only FDA-approved prescription eye drop ...

Nicox completed the Denali Phase 3 trial for NCX 470, targeting open-angle glaucoma and ocular hypertension. NCX 470 combines ...

A new study demonstrates that handheld nanopore sequencers can rapidly identify eye infection pathogens using only a patient’s tears.

Through the program, gene therapies are developed to treat patients with retinitis pigmentosa caused by pathogenic variants ...

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a ...

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair ...

From Nobel laureates to AI-driven research, the Wilmer Eye Institute honors a century of transforming vision science and care ...

The trial is evaluating KB803 for the treatment and prevention of corneal abrasions in dystrophic epidermolysis bullosa ...

Kodiak Sciences showcases KSI-101, a potential new treatment for macular edema, at the 2025 IOIS Congress, aiming to better ...

The ophthalmic drug development industry is undergoing significant transformation, marked by unprecedented advancements in ...